This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Translational Prostate Cancer
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Clinical Trials
From the Editor
Search Clinical Trials
Trials in Progress
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Oral EPI-7386
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2022
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Video Lectures
PSMA Targeted Therapy
The Implementation of PSMA Theranostics in Clinical Practice - Oliver Sartor
July 19, 2022
Details
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
June 16, 2022
Details
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
April 3, 2022
Details
Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor
March 28, 2022
Details
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
March 10, 2022
Details
Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo
December 16, 2021
Details
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
October 15, 2021
Details
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
October 3, 2021
Details
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
August 12, 2021
Details
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
July 20, 2021
Details
Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor
June 23, 2021
Details
The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor
June 7, 2021
Details
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
June 4, 2021
Details
177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman
March 22, 2021
Details
Targeted Radionuclide Therapy of Prostate Cancer - Wolfgang Weber
June 21, 2020
Details
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis
May 29, 2020
Details
TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer - Michael Hofman
May 8, 2020
Details
Targeted Molecular Therapies for Treatment of Advanced Prostate Cancer - Scott Tagawa
March 30, 2020
Details
The Evolving Role of Lutetium-PSMA in the Era of Personalized Medicine - Michael Hofman
March 30, 2020
Details
Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni
January 8, 2020
Details
Outcomes of Patients From PSMA Targeted Radionuclide Trials - Panagiotis Vlachostergios
August 8, 2020
Details
High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman
December 27, 2019
Details
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
November 18, 2019
Details
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
October 31, 2019
Details
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
October 14, 2019
Details
PSMA Targeted Therapies Presentation - Michael Hofman
September 18, 2019
Details
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
February 25, 2019
Details
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais
February 4, 2019
Details
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
